DavidCCarterMD

Journal Articles

• A first-in-human study of the novel immunology antibody–drug conjugate, ABBV-3373, in healthy participants  
  Ronilda D'Cunha, Hartmut Kupper, Dilek Arikan, Weihan Zhao, David Carter, Jonas Blaes, Melanie Ruzek, Yinuo Pang, British Journal of Clinical Pharmacology, 8/18/2023
• Identification of Drug-Induced Multichannel Block and Proarrhythmic Risk in Humans Using Continuous T Vector Velocity Effect Profiles Derived From Surface Electrocardi...  
  Bystricky Werner, Maier Christoph, Gintant Gary, Bergau Dennis, Carter David, Frontiers in Physiology, 9/18/2000
• A first‐in‐human study of the novel immunology antibody–drug conjugate, ABBV‐3373, in healthy participants  
  Ronilda D'Cunha, Hartmut Kupper, Dilek Arikan, Weihan Zhao, David Carter, Jonas Blaes, Melanie Ruzek, Yinuo Pang, British Journal of Clinical Pharmacology, 8/18/2023
• A Phase-I pharmacokinetic, safety and food-effect study on flubentylosin, a novel analog of Tylosin-A having potent anti-Wolbachia and antifilarial activity  
  Niki Alami, David Carter, Nisha V. Kwatra, Weihan Zhao, et.al., PLOS Neglected Tropical Diseases, 7/10/2023
• Effects of a ritonavir-containing regimen on the pharmacokinetics of sirolimus or everolimus in healthy adult subjects  
  Jiuhong Zha, Qi Jiang, Betty B. Yao, Daniel E. Cohen, David C. Carter, Rajeev M. Menon, Pharmacology Research and Perspectives, 11/23/2022
• T vector velocity: A new ECG biomarker for identifying drug effects on cardiac ventricular repolarization  
  Werner Bystricky, Christoph Maier, Gary Gintant, Dennis Bergau, Kent Kamradt, Patrick Welsh, David Carter, PLOS ONE, 7/8/2019
• Join now to see all